UY30579A1 - Formulacion acuosa que comprende un agente antitumoral - Google Patents

Formulacion acuosa que comprende un agente antitumoral

Info

Publication number
UY30579A1
UY30579A1 UY30579A UY30579A UY30579A1 UY 30579 A1 UY30579 A1 UY 30579A1 UY 30579 A UY30579 A UY 30579A UY 30579 A UY30579 A UY 30579A UY 30579 A1 UY30579 A1 UY 30579A1
Authority
UY
Uruguay
Prior art keywords
antitumoral agent
watery
understanding
formulation understanding
watery formulation
Prior art date
Application number
UY30579A
Other languages
English (en)
Inventor
William L Rocco
Liu Jiping
Dorchies Olivier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY30579A1 publication Critical patent/UY30579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones y formulaciones farmacéuticas que comprenden ácido (2R)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico, y métodos de uso de las mismas.
UY30579A 2006-09-07 2007-09-07 Formulacion acuosa que comprende un agente antitumoral UY30579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291410A EP1897542A1 (en) 2006-09-07 2006-09-07 Aqueous formulation comprising an antitumor agent

Publications (1)

Publication Number Publication Date
UY30579A1 true UY30579A1 (es) 2008-03-31

Family

ID=37728353

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30579A UY30579A1 (es) 2006-09-07 2007-09-07 Formulacion acuosa que comprende un agente antitumoral

Country Status (16)

Country Link
EP (2) EP1897542A1 (es)
JP (1) JP2010502691A (es)
KR (1) KR20090050070A (es)
CN (1) CN101511362A (es)
AR (1) AR062674A1 (es)
AU (1) AU2007293174A1 (es)
BR (1) BRPI0717034A2 (es)
CA (1) CA2660685A1 (es)
CL (1) CL2007002598A1 (es)
IL (1) IL197072A0 (es)
MX (1) MX2009002280A (es)
PE (1) PE20081366A1 (es)
RU (1) RU2009112624A (es)
TW (1) TW200817005A (es)
UY (1) UY30579A1 (es)
WO (1) WO2008029282A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2456173A1 (en) * 2001-07-31 2003-02-13 Wayne State University Quinoline derivatives and use thereof as antitumor agents
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents

Also Published As

Publication number Publication date
CL2007002598A1 (es) 2008-04-18
JP2010502691A (ja) 2010-01-28
PE20081366A1 (es) 2008-11-28
RU2009112624A (ru) 2010-10-20
AR062674A1 (es) 2008-11-26
MX2009002280A (es) 2009-03-13
CA2660685A1 (en) 2008-03-13
AU2007293174A1 (en) 2008-03-13
EP1897542A1 (en) 2008-03-12
EP2068876A2 (en) 2009-06-17
WO2008029282A2 (en) 2008-03-13
IL197072A0 (en) 2009-11-18
CN101511362A (zh) 2009-08-19
TW200817005A (en) 2008-04-16
BRPI0717034A2 (pt) 2014-05-20
WO2008029282A3 (en) 2008-05-22
KR20090050070A (ko) 2009-05-19

Similar Documents

Publication Publication Date Title
EA200702198A1 (ru) Фармацевтические составы
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
EA201500430A1 (ru) Соединения боронатного эфира и его фармацевтические составы
AR045068A1 (es) Formulacion de liberacion inmediata de composiciones farmaceuticas
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
MEP18208A (en) Immune response modifier foam formulations
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
DE60213114D1 (de) Herbizidzusammensetzung,umfassend herbizide verbindung in säureform und ansäuerndes mittel,applizierverfahren und herstellungsverfahren davon
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
EP2349279A4 (en) ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
BRPI0507198A (pt) derivados de bisariluréia
NO20075111L (no) Farmasoytisk sammensetning
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
ATE429906T1 (de) Trockene aripiprazolformulierungen
EA200900267A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
BR112015013689A2 (pt) composições fluidas de cuidado oral contendo peróxido
BR112013019394A2 (pt) uso de um agente
EA201070378A1 (ru) Фармацевтические составы орлистата
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
UY30579A1 (es) Formulacion acuosa que comprende un agente antitumoral

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130225